Avalo Therapeutics (AVTX)

• Market cap: $125M
• 1 day: 1.06%
• 5 days: 8.08%
• 1 month: 44.38%
• 3 months: 162.43%
• 6 months: 41.79%
• Year to date: 12.69%
• 1 year: -5.00%
• 5 years: -99.87%
• 10 years: -99.92%
• Sector: Healthcare
• Industry: Biotechnology

About: Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Employees: 23

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

6% more funds holding

Funds holding: 34 [Q1] → 36 (+2) [Q2]

4.93% less ownership

Funds ownership: 77.37% [Q1] → 72.44% (-4.93%) [Q2]

25% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 12

41% less capital invested

Capital invested by funds: $66.1M [Q1] → $39.1M (-$27M) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $15 58% upside
• Avg. target: $15 58% upside
• High target: $15 58% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor

58% upside $15

Buy Assumed

2 Jun 2025